Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: New insights into de novo resistance to trastuzumab (Herceptin)

CRISTINA OLIVERAS-FERRAROS1,2*, ALEJANDRO VAZQUEZ-MARTIN1,2*, BEGOÑA MARTIN-CASTILLÓ1,2*, MARIA CARMEN PÉREZ-MARTÍNEZ1,2, SILVIA CUFF1,2, SONIA DEL BARCO1,2, LUIS BERNADO2,3, JOAN BRUNET1,2, EUGENI LÓPEZ-BONET2,3 and JAVÍER A. MENENDEZ1,2

1Catalan Institute of Oncology (ICO); 2Girona Biomedical Research Institute (IdIBGi); 3Department of Pathology, Dr Josep Trueta University Hospital of Girona, Avenida de Francia S/N, E-17007 Girona, Catalonia, Spain

Received May 3, 2010; Accepted June 2, 2010

DOI: 10.3892/ijo_00000716

Abstract. Pioneering clinical studies in de novo refractoriness to the anti-HER2 monoclonal antibody trastuzumab have suggested that HER2 gene-amplification can take place also in a basal-like molecular background to generate basal/HER2+ tumors intrinsically resistant to trastuzumab. Here, we first investigated the unique histogenesis of the basal/HER2+ phenotype in breast carcinomas. The presence of basal CK5/CK6 cytokeratin expression in HER2+ tumors revealed a significant overlap in the histological features of HER2+/CK5/6+ and basal-like breast carcinomas. Basal/HER2+ tumors were typically poorly differentiated, high-grade invasive ductal carcinomas with large geographic necrosis, pushing margins of invasion, syncytial arrangement of tumor cells, ribbon- or festoon-like architecture, squamous metaplasia, stromal lymphocytic infiltrates, high mitotic index and strong p53 positivity. Secondly, we performed low-scale proteomic approaches in JIMT-1 cells, a unique model of HER2-gene amplified trastuzumab-resistant breast carcinoma with a basal-like phenotype, to develop biomarker signatures that may differentiate trastuzumab-responsive from non-responsive tumors. When applying antibody-based array technology to the extracellular milieu of trastuzumab-refractory JIMT-1 and trastuzumab-sensitive SKBR3 cell cultures, JIMT-1 cells were found to secrete higher amounts of several growth factors including amphiregulin, EGF, IGFBP-6, PDGF-AA, neurotrophins, TGFβ and VEGF. Semi-quantitative signaling node multi-target sandwich ELISAs revealed that JIMT-1 cells drastically overactivate RelA, the prosurvival subunit of NF-κB as compared to trastuzumab-sensitive luminal/HER2- SKBR3 cells. When simultaneously assessing the activation status of 42 receptor tyrosine kinases (RTK) using a human phospho-RTK array, JIMT-1 cells were found to constitutively display hyperactivation of the insulin-like growth factor-I receptor (IGF-1R). High-content immunofluorescence imaging revealed that activated IGF-1R mainly localized at focal adhesion-like structures in JIMT-1 cells. In vitro wound healing assays suggested that this functional reorganization of the JIMT-1 cytoskeletal reorganization may account for an exacerbated trastuzumab-refractory ‘migratogenic’ phenotype. Forthcoming studies should validate the notion that identification of basal-like immunophenotypes and/or basal-like molecular signatures within HER2+ breast carcinomas may provide rapid means to define subgroups of breast cancer patients likely to display resistance to trastuzumab ab initio.

Introduction

Clinical benefit of using the anti-HER2 monoclonal antibody trastuzumab (Herceptin) is limited by the fact that secondary (i.e. acquired) resistance develops rapidly (within 1 year) in most of trastuzumab-treated HER2+ SKBR3 breast cancer patients (1-4). On the other hand, 70% of HER2-overexpressing metastatic breast carcinomas show primary resistance to trastuzumab as a single agent and approximately 15% of women diagnosed with early HER2+ breast cancer are de novo resistant to trastuzumab and relapse in spite of treatment with trastuzumab-based therapies (5,6). Although significant amount of pre-clinical and clinical research has been dedicated to elucidate molecular mechanisms that could explain the appearance of acquired resistance to trastuzumab (7-10), there have been few studies addressing the ultimate molecular mechanisms that could explain de novo (i.e. intrinsic or primary) resistance to trastuzumab (11-13). Indeed, HER2 status yet remains as the only available biomarker for selecting breast cancer patients for trastuzumab-based therapy.
Pioneering findings by Harris and colleagues demonstrated that HER2-overexpressing tumors with a basal-like phenotype and/or with expression of insulin-like growth factor-I receptor (IGF-IR) and other proteins involved in growth factor pathways were more likely to be intrinsically resistant to pre-operative trastuzumab (14). Lesniak and colleagues recently demonstrated that overexpression of B1 integrin, an adhesion molecule involved in cell migration, invasion, spreading and signaling in prototypical basal-like breast carcinomas, is an independent negative prognostic factor for tumor progression of HER2+ metastatic breast cancer patients treated with trastuzumab-based chemotherapy (15). Although microarray studies have repeatedly classified HER2+ breast carcinomas as a molecular entity separate from basal-like tumors (16-18), the above-mentioned clinical findings strongly suggest that HER2 gene-amplification could take place also in a basal-like molecular background (19,20).

Here, we sought to confirm and expand the clinical notion that a mixed basal/HER2+ molecular scenario may account for refractoriness to HER targeting therapies ab initio. First, we sought to confirm that histologic features of some HER2+ breast carcinomas significantly overlap those attributed solely to basal-like tumors (21,22). Second, low-scale proteomic approaches were performed for biomarker discovery in cultured JIMT-1 cells, a unique model of HER2-gene amplified breast carcinoma with a basal-like phenotype (23).

Materials and methods

**Immunohistochemistry.** Breast cancer tissues including core biopsies and surgical specimens were analyzed for HER2, CK5/6, p53 using standardized immunohistochemical techniques and robotic autostainers (Dako Cytomation, Inc.). Briefly, 3-μm sections of the cancer tissue were placed on positively charged glass microscope slides. Deparaffinization involved incubation of the slides in xylene followed by graded alcohol series in a routine manner. Endogenous peroxidase activity was blocked with 3% hydrogen peroxidase and methanol. Samples were steamed for antigen retrieval with 10 mM citrate buffer (pH 6.0) for 30 min. Following protein block, slides were incubated with antibodies for ER, PR, HER2, p63 and CK5/6. Binding results were visualized with the Envision® System (Dako Cytomation, Inc.), which uses horseradish peroxidase-labelled polymer that is conjugated with secondary antibodies. 3,3′-diaminobenzidine tetrahydrochloride (DAB) was used as a visualization of the antibody/antigen complex. Slides were counterstained with hematoxylin and examined by light microscopy. Tumor immunoreactivity was scored 0, negative; 1, weak positive; and 2, moderate/strong positive in combination with the percent of cells showing positive staining.

**Histopathology.** Hematoxylin- and eosin-stained slides were evaluated under light microscopy. Breast carcinomas were evaluated for grade [1-3] using the modified Scarff-Bloom-Richardson grading system comprising an architectural grade, nuclear grade and mitotic grade. Mitotic counts were performed using the x40 objective on an Olympus BH-2 microscope. Breast cancer tissues were also evaluated for tumor histologic type, presence of geographic necrosis, quantity of apoptotic cells, border appearance, lymphocytic stromal response, nucleoli, nuclear chromatin pattern, apocrine features, metaplastic features, large central acellular zone and medullary features.

**Cell lines and culture conditions.** SKBR3 human breast cancer cells were obtained from the American Type Culture Collection (ATCC) and they where routinely grown in improved MEM (IMEM; BioSource International; Invitrogen S.A., Barcelona, Spain) supplemented with 5% fetal bovine serum (FBS) and 2 mM L-glutamine. JIMT-1 human breast cancer cell line was established at Tampere University and is available from the German Collection of Microorganisms and Cell Cultures (http://www.dsmz.de/). JIMT-1 cells were grown in F-12/DMEM (1:1) supplemented with 10% FBS and 2 mM L-glutamine. Cells were maintained at 37°C in a humidified atmosphere of 95% air and 5% CO2. Cells were screened periodically for Mycoplasma contamination.

**Antibody-based arraying of growth factors/secreted growth factor receptors.** To prepare conditioned media, SKBR3 and JIMT-1 cells were plated in 100-mm tissue culture dishes and cultured in regular media with 5% FBS until they reached 75-80% confluence. Cells were washed twice with serum-free media, and incubated overnight in serum-free IMEM (SKBR3) or F-12/DMEM (JIMT-1). Cells were then cultured for 48 h in low-serum (i.e., 0.1% FBS) media. The supernatant were collected, centrifuged at 1,000 x g, aliquoted, and immediately stored at -80˚C until utilization. RayBio® human growth factors/secreted growth factor receptors array 1 was purchased from RayBiotech, Inc. (Norcross, GA, USA) and antibody-based arraying was carried out as per manufacturer's instructions. Briefly, membranes were blocked with 5% BSA/TBS (0.01 M Tris HCl, pH 7.6/0.15 M NaCl) for 1 h. Membranes were then incubated with ~2 ml of conditioned media prepared from SKBR3 and JIMT-1 cell lines after normalization with equal amounts of protein for 2 h. After extensive washing with TBS/0.1% v/v Tween-20 (3 times, 5 min each) and TBS (2 times, 5 min each) to remove unbound materials, the membranes were incubated with a cocktail of biotin-labeled antibodies against different individual cytokines/metalloproteases. The membranes were then washed and incubated with HRP-conjugated streptavidin (2.5 pg/ml) for 1 h at room temperature. Unbound HRP-streptavidin was washed out with TBS/0.1% Tween-20 and TBS. Finally the signals were detected by ECL system. Densitometric values of spots were quantified using Kodak Image Analysis Software (Kodak).

**Semi-quantitative determination of AKT, Stat3, p38 MAPK, MEK1 and NF-κB phosphorylation status.** CST’s PathScan® Signaling Nodes Multi-Target Sandwich ELISA Kit no. 7272 was purchased from Cell Signaling Technology, Inc. This solid phase sandwich enzyme-linked Immunosorbent assay combines the reagents necessary to detect endogenous levels of AKT1, phospho-AKT1 (Ser473), phospho-MEK1 (Ser217/221), phospho-p38 MAPK (Thr180/Tyr182), phospho-Stat3 (Tyr705) and phospho-NF-κB p65 (Ser536). SKBR3 and JIMT-1 cells (75-80% confluent) were starved overnight and...
then cultured in the absence or presence of 100 μg/ml trastuzumab in low-serum (0.1% FBS)-containing culture medium for 48 h. Cells were washed twice with cold-PBS and then lysed in buffer [20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 μg/ml leupeptin, 1 mM phenylmethylsulfonylfluoride, and complete protease inhibitor cocktail (Sigma-Chemicals)] for 30 min on ice. The lysates were cleared by centrifugation in an Eppendorff tube (15 min at 14,000 x g, 4°C). Protein content was determined against a standardized control using the Pierce Protein Assay Kit (Rockford, IL, USA). Differential phosphorylation of AKT1, phospho-AKT, phospho-an Eppendorff tube (15 min at 14,000 x g, 4˚C). Protein content was determined against a standardized control using the Pierce Protein Assay Kit (Rockford, IL, USA).

Antibody array-based profiling of phospho-receptor tyrosine kinases (RTKs). SKBR3 and JIMT-1 cells were plated in 100-mm tissue culture dishes and cultured in regular media containing 10% FBS until they reached 75-80% confluence. The cells were then then incubated twice with serum-free medium and incubated overnight upon serum-free conditions. Cells were then stimulated to grow in 5% FBS-containing medium in the presence or absence of 100 μg/ml trastuzumab for 48 h. Cells were rinsed with cold phosphate-buffered saline (PBS) and immediately solubilized in NP-40 lysis buffer [1% NP-40, 20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 10% glycerol, 2 mM Triton X-100, 1 mM sodium orthovanadate, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 1 mM phenylmethyl-sulfonylfluoride, and complete protease inhibitor cocktail (Sigma-Chemicals)] by rocking the lysates gently at 4°C for 30 min. Following microcentrifugation at 14,000 x g for 5 min, supernatants were transferred into a clean test tube and sample protein concentrations were determined using the Pierce Protein Assay Kit (Rockford, IL, USA). Lysate (500 μg) was diluted and incubated with the Human Phospho-RTK Array Kit (Proteome Profiler; R&D Systems, Minneapolis, MN, USA) as per the manufacturer's instructions. Arrays data were developed on X-ray film following exposure to chemiluminescent reagents.

Immunofluorescence staining and high-content confocal imaging. Cells were seeded at approximately 5,000 cells/well in 96-well clear bottom imaging tissue culture plates (Becton-Dickinson Biosciences; San Jose, CA, USA) optimized for automated imaging applications. Triton X-100 permeabilization and blocking, primary antibody staining, secondary antibody staining using Alexa Fluor® 488/594 goat anti-rabbit/mouse IgGs (Invitrogen, Molecular Probes, Eugene, OR, USA) and counterstaining (using Hoechst 33258; Invitrogen) were performed following BD Biosciences protocols. Images were captured in different channels for Alexa Fluor 488 (pseudo-colored green), Alexa Fluor 594 (pseudo-colored red) and Hoechst 33258 (pseudo-colored blue) on a BD Pathway™ 855 Bioimager System (Becton-Dickinson Biosciences) with 20 or x40 objectives (NA 075 Olympus). Both acquisition and merging of images were carried out according to the Recommended Assay Procedure using BDAttovision™ software. We employed the following antibodies: 1:50 dilution of anti-PP-IGF-IR (Tyr 1161) (sc-101703; Santa Cruz Biotechnology, Santa Cruz, CA, USA), 1:40 dilution of Alexa Fluor 594 Phalloidin (A12381; Invitrogen), and 1:400 dilution of anti-vinculin (V9264, clone hVIN-1, Sigma-Aldrich, St. Louis, MO, USA)

Wound-healing motility assays. Cells were seeded onto six-well dishes at 1x10⁴ per well. A single scratch wound was created using a p10 micropipette tip into confluent cells. Cells were washed thrice with PBS to remove cell debris, supplemented with assay medium in the absence or presence of 100 μg/ml trastuzumab, and monitored. Images were captured by phase-contrast microscopy at 0, 24 and 48 h after wounding.

Results

A subgroup of HER2-overexpressing breast carcinomas overlaps in the histologic features of the basal-like phenotype. Preliminary studies using formalin-fixed, paraffin-embedded block tissues from the cancer tissue collection in our Department of Pathology at the Dr Josep Trueta University Hospital of Girona confirmed that ER/PR-negative HER2+ breast carcinomas exist that simultaneously express basal epithelium cytokeratins markers (e.g. CK5/CK6) (21,24). In some cases, HER2+ breast tumors that stained positively for basal keratins displayed a focal checkerboard pattern with CK5/CK6-negative and CK5/CK6-positive tumor cells located next to each other (Fig. 1A). Interestingly, some HER2+-positive tumors stained uniformly or almost uniformly with CK5/CK6, thus resembling pure basal-like breast carcinomas. Indeed, this subgroup of HER2+ breast carcinomas displayed histological features of basal-like tumors: They were typically poorly differentiated, high-grade invasive ductal carcinomas with large geographic necrosis, pushing margins of invasion, symmetrical arrangement of tumor cells, ribbon- or festoon-like architecture, squamous metaplasia, stromal lymphocytic infiltrates, high mitotic index (ranging from 19 mitoses/10 high-power fields to 32 mitoses/10 high-power fields) and strong p53 positivity (Fig. 1B) (22,25). Some of the histopathological features found in the basal/HER2 subgroup closely resembled those previously reported in medullary (lymphocytic infiltrate and pushing margins) or metaplastic (squamous metaplasia) breast carcinomas, two rare types of breast cancer with a well-recognized basal-like immunohistochemical profile (26).
a first attempt to pre-clinically discover novel biomarkers that could be employed for functionally studying HER2+/basal-like breast carcinomas with primary refractoriness to trastuzumab, we took advantage of the intrinsic trastuzumab resistance in a cell line isolated from the pleural fluid of a HER2-positive breast cancer patient with progressive disease on Tzb (i.e. JIMT-1) (Fig. 2). Despite its paradoxical HER2 gene amplification, ER/PR-negative JIMT-1 cells have repeatedly been classified as basal-like breast cancer cells mainly due to the fact that they express both basal CK5/CK14 and luminal CK8/CK18 cytokeratins (11,13). High-resolution genomic profiles have confirmed that JIMT-1 cells have the closest resemblance to the HER2+ breast cancer subtype but also to the stem/progenitor (basal-like) breast tumors (23). Indeed, HER2-gene amplified JIMT-1 cells display several of the molecular features distinctively associated with the unique histogenesis of basal-like breast carcinomas including a strong positivity for p53 and high levels of vimentin and p63 expression. Here, we performed low-scale proteomic analyses to obtain pathway-focused molecular signatures in JIMT-1 cells as well as in SKBR3 cells, a widely-used in vitro model of HER2 overexpression exquisitely sensitive to the growth inhibitory actions of trastuzumab.

**Growth factor secretome signature.** We applied antibody-based array systems to identify growth factors/secreted growth factor receptor signatures in HER2+ (basal-like) JIMT-1 breast cancer cells when compared to HER2+ (luminal) SKBR3 breast cancer cells (Fig. 3A). JIMT-1 cells drastically up-regulated, among other ligands belonging to the epidermal growth factor (EGF)-like and fibroblast growth factor (FGF) families, the secretion of amphiregulin and EGF. JIMT-1 cells secreted also enormous amounts of the insulin growth factor binding protein-6 (IGFBP-6) and significantly up-regulated the secretion of the neurotrophins NT-3 and NT-4. Interestingly, we noted a switch between the main platelet-derived growth factor (PDGF) isoform expressed in JIMT-1 (PDGF-AA) and SKBR3 (PDGF-BB) cells, respectively. When compared to SKBR3 cells, pro-angiogenic features were clearly noted in the secretome of JIMT-1 cells as they up-regulated all the isoforms (β1, β2 and β3) of the indirect...
angiogenic agent TGF (transforming growth factor) as well as the well-recognized angiogenic effector VEGF (vascular endothelial growth factor) and its receptor (VEGF-R2).

Intracellular signaling nodes. We assessed the activation status of convergence points and key regulatory proteins in several signaling pathways controlling cellular events such as growth and differentiation, energy homeostasis and the response to stress and inflammation (Fig. 3B). We took advantage of the CST's PathScan® Signaling Nodes Multi-Target Sandwich ELISA kit (Cell Signaling Technology, Inc.) to simultaneously assess, in a semi-quantitative manner, the endogenous levels of AKT1, phospho-AKT1 (Ser473), phospho-MEK1 (Ser217/221), phospho-p38 MAPK (Thr180/Tyr182), phospho-Stat3 (Tyr705) and phospho-NF-κB p65 (Ser536) in Tzb-naive SKBR3 cells and Tzb-resistant JIMT-1 cells. JIMT-1 cells not only expressed significantly lower levels of total AKT1 protein but they displayed further a very low phospho-activity profile in all convergence signaling points regulated by MEK1, p38 MAPK and Stat3 proteins when compared to trastuzumab-sensitive SKBR3 cells. Trastuzumab treatment failed to significantly alter constitutive low levels of phospho-AKT1/-MEK1/-p38 MAPK and -Stat3 in JIMT-1 cells (data not shown). Interestingly, JIMT-1 cells displayed a drastic overactivation of NF-kB p65 when compared to SKBR3 cells. High levels of NF-kB p65 remained unaltered following treatment of JIMT-1 cells with trastuzumab (data not shown).

Receptor tyrosine kinase (RTK) phospho-proteome signature. We evaluated whether activation/deactivation of HER network-related receptor tyrosine kinases (RTKs) might significantly differ in trastuzumab-refractory JIMT-1 cells and trastuzumab-naive SKBR3 cells. To simultaneously assess the activation status of multiple RTKs, we took advantage of the human phospho-RTK array, a semi-quantitative tool able to simultaneously identify the phosphorylation status of 42 RTKs in a rapid and sensitive manner (Fig. 4A). In untreated SKBR3 breast cancer cells, the three members of the HER network HER1 (EGFR), HER2 and HER3 were likewise highly phosphorylated, and HER2 phosphorylation was completely suppressed in the presence of trastuzumab. Trastuzumab treatment slightly reduced HER3 trans-activation and slightly increased the phosphorylation status of insulin receptor (IR) and insulin growth factor-1 receptor (IGF-1R). In marked contrast, phospho-RTK profiling of cell lysates from untreated JIMT-1 cells clearly revealed that, unlike HER1 (EGFR) activity, the constitutive status of
HER2 and HER3 phosphorylation was markedly decreased compared to that observed in untreated SKBR3 cells. While treatment trastuzumab was sufficient to abrogate the slight HER2 phosphorylation, JIMT-1 cells exhibited a trastuzumab-refractory hyperactivation of IR and IGF-1R, thus suggesting that the insulin signaling-related cytoprotective stress response observed in trastuzumab-naive SKBR3 cells is constitutively up-regulated in JIMT-1 cells.

Bio-functional imaging of phospho-IGF-1R in basal/HER2+ JIMT-1 cells. Because the hyper-phosphorylated status of IR/IGF-1R, which could compensate for attenuated HER2 signaling in trastuzumab-refractory JIMT-1 cells, remained unaltered in the presence of trastuzumab, and because co-staining experiments failed to demonstrate co-localization of PP-IGF-1R Tyr1161 and HER2 (data not shown), we speculated that signaling emanating from the insulin/IGF-1 transduction cascade could take place in separated sub-cellular compartments functionally unrelated to HER signaling platforms in trastuzumab-refractory JIMT-1 cells. In agreement with this notion, we observed striking accumulations of PP-IGF-1R Tyr1161 at numerous and distinct cell membrane-associated plaques when performing high-content immunofluorescence microscopy studies to visualize sub-cellular accumulation of the active form of IGF-1R before and after treatment with trastuzumab (Fig. 4B). This phenomenon, however, occurred exclusively in trastuzumab-resistant JIMT-1 cells but not in trastuzumab-sensitive SKBR3 cells.

Co-staining experiments with antibodies directed against phosphorylated IGF-1R and the cytoskeletal protein F-actin strongly suggested that trastuzumab-refractory JIMT-1 cells appear to exhibit a significant reorganization of the cytoskeleton when compared that observed in trastuzumab-sensitive SKBR3 cells. Whereas trastuzumab-enhanced IGF-1R phosphorylation formed continuous lines along the borders of cell-cell contacts in SKBR3 cells (where F-actin was also
localized extensively), JIMT-1 cells had punctuated instead of continuous distribution of PP-IGF-1R Tyr1161 at cell-cell borders with F-actin concentrating within membrane protrusions (Fig. 5A). Indeed, co-staining experiments with the cytoskeletal protein vinculin confirmed further that PP-IGF-1R Tyr1161 somewhat concentrated at the edges of profuse and numerous focal adhesions-like structures in the cell membrane of JIMT-1 cells (Figs. 5B and 6A). These phenomena might relate to changes in the cell migratory behavior of JIMT-1 cells. In vitro scratch wound healing assays showed a significantly faster migration rate in JIMT-1 basal-like cells compared to the very low locomotory activity of SKBR3 luminal cells (data not shown). Perhaps more importantly, the highly migratogenic phenotype of JIMT-1 cells took place irrespective of the absence or presence of trastuzumab (Fig. 6B).

Discussion

It is well recognized that breast cancer disease exhibits a heterogeneous clinical, histological and molecular diversity. Gene expression profiling and biomarker studies have repeatedly shown, at least, five distinct molecular subtypes of breast cancer: luminal A (ER+ and/or PR+, HER2−), luminal B (ER+ and/or PR+, HER2+), HER2-overexpressing (ER/PR-, HER2+), basal-like (ER/-PR-, HER2-, CK5/CK6+ and/or EGFR+) and normal breast-like tumors. Since different keratins predominate in the different lineages of the normal breast, with CK18 and CK19 being expressed in the luminal cells and CK5/CK6 and CK14 in basal/myoepithelial cells, breast carcinomas can also be broadly categorized into two
classes: those that express luminal keratins (luminal-type) and those that express stratified epithelial keratins (basal-like). In this scenario, it has been suggested that a subset of HER2+ breast carcinomas should originate from luminal cells with HER2 gene amplification and HER2 protein overexpression being a relatively late event in HER2+ breast cancer tumorigenesis. However, it is well recognized that HER2 overexpression frequently occurs in premalignant lesions, such as DCIS, and overexpression of HER2 significantly increases the fraction of breast cancer cells positive for ALDH1 (aldehyde dehydrogenase), a marker of normal and cancerous human mammary epithelial cells with stem/progenitor properties (27). Our current confirmation of the presence of basal cytokeratins (i.e. CK5/CK6) in HER2+ breast carcinomas, thus denoting a basal/HER2+ phenotype that has been shown recently to exhibit poorer survival than basal-like phenotype in hormone receptor-negative invasive breast carcinomas (24), therefore raises the possibility that these tumors may originate from stem cells that subsequently undergo variable degrees of basal and luminal differentiation.

Given that prognostic features of the basal/HER2+ phenotype might be intrinsically different to those found in either HER2+ or basal-like breast carcinomas, it would be reasonable to suggest that this group of tumors might require different treatment strategies. Indeed, the presence of a basal/HER2+ phenotype may largely explain the pioneer finding that a subset of tumors may originate from stem cells that subsequently undergo variable degrees of basal and luminal differentiation. Given that prognostic features of the basal/HER2+ phenotype might be intrinsically different to those found in either HER2+ or basal-like breast carcinomas, it would be reasonable to suggest that this group of tumors might require different treatment strategies. Indeed, the presence of a basal/HER2+ phenotype may largely explain the pioneer finding that a subset of tumors may originate from stem cells that subsequently undergo variable degrees of basal and luminal differentiation.

Harris and colleagues reported that HER2+ tumors with de novo refractoriness to trastuzumab expressed higher levels of growth factors including IGF-1, hepatocyte growth factor, PDGF and pleiotrophin (14). Although virtually nothing is known about the paracrine/autocrine/intracrine actions of growth factors in the efficacy of HER targeting agents, we are beginning to accumulate evidence that the efficacy of anticaner drugs that block one or several members of the HER network may be compromised by the presence of EGFR-related ligands (28-30). Motoyama and colleagues conducted pioneering work in demonstrating that the growth-inhibitory effects of HER1/HER2 tyrosine kinase inhibitors (TKIs) are significantly attenuated in the presence of exogenous heregulin, which is a high-affinity combinatorial ligand for HER3 and HER4 receptors in breast cancer cells (31). Within the same context of HER-targeting inhibitors, it has been observed that breast cancer cells with acquired resistance to trastuzumab express higher endogenous levels of EGFR-related ligands as compared with parental, trastuzumab-sensitive cells (32). We and others have demonstrated that the growth-inhibitory effects of HER inhibitors indeed correlate with expression levels of certain HER ligands (29,30). JIMT-1 breast cancer cells not only exhibit primary resistance to trastuzumab but demonstrate further cross-resistance to several HER2-inhibiting drugs including the HER-dimerization inhibitor antibody pertuzumab (2C4) and the small molecule HER TKIs CI1033 (canertinib), ZD1839 (gefitinib) and lapatinib (11,33). It is noteworthy that, when compared to HER2+ SKBR3 cells, a luminal breast cancer model exquisitely sensitive to HER targeting agents including trastuzumab, gefitinib and lapatinib, the JIMT-1 secretome accumulated significantly higher amounts of several growth factors such as amphiregulin and EGF (two high-affinity ligands of EGFR (HER1), a growth factor receptor commonly found overexpressed in basal-like breast tumors) as well as several isoforms of the pro-angiogenic factors TGFß and VEGF. Most of these secreted factors are important components of the tumor-stromal microenvironment and, in vivo, they may play yet to be explored mitogenic and chemotactic effects that may account for resistance to trastuzumab-based therapy.

Extensive preclinical and limited clinical data have suggested that IGF-1R is associated with acquired (i.e. secondary) auto-resistance to trastuzumab (1-4,6,7). In a scenario of trastuzumab resistance ab initio, Harris and colleagues reported that finding either IGF-1 gene overexpression by array or IGF-1R protein expression on the membrane in trastuzumab-resistant tumors might suggest the presence of an autocrine loop in which IGF-1R signaling actively mediates de novo resistance to trastuzumab therapy (14). Here, by using low-scale phospho-proteomic analyses, we reveal that trastuzumab-refractory basal/HER2+ JIMT-1 cells display a reduced signaling through HER2 that is accompanied by constitutive and trastuzumab-insensitive hyperactivation of the alternative signaling cascade IR/IGF-1R. Initially, the significance of this finding was unclear because constitutive hyperactivation of IR/IGF-1R failed to associate with an enhanced activation of both mitogen-activated protein kinase (MAPK) and AKT pathways, which are critical for HER2 signal transduction. Rather, IR/IGF-1R hyperactivation in basal/HER2+ breast carcinomas may release these tumors from dependence on HER2 for proliferation and survival through two novel pathways. On the one hand, JIMT-1 cells drastically overactivated RelA, a prosurvival subunit of NF-xB, a recently discovered cytoprotective stress response that confers resistance to the dual HER1/HER2 TKI lapatinib (34). On the other hand, unlike uniform localization of activated IGF-1R in the cell membrane of trastuzumab-treated luminal/HER2+ SKBR3 cells, activated IGF-1R mainly localized at numerous and profuse focal adhesions, like structures in basal/HER2+ JIMT-1 cells, which exhibited a significant cytoskeleton reorganization accompanied by an exacerbated trastuzumab-refractory migratogenic phenotype. Our findings support the notion that basal-like breast carcinomas exhibit high motility and invasive properties as well as the accumulating evidence that the IGF/IGF transduction node functions not only as mitogenic factor but also as promotor of cell motility (35-38). It has been shown that activated IGF-1R associates to and activates integrins at the focal adhesion contacts, probably acting through cytoskeletal proteins such as vinculin. As a consequence of cell adhesion,
autophosphorylation of focal adhesion kinase (FAK) takes place and focal adhesions are assembled. Our current bio-
functional imaging analyses suggest that this straightforward sequence of events could explain how constitutive IGF-1R hyperactivation may stimulate JIMT-1 cell migration. Recent studies have revealed that trastuzumab treatment is sufficient to abrogate lamellipodia formation and MMP-independent cell migration in HER2 gene-amplified breast cancer cells (39). Moreover, intracellular signaling emanating from FAK may mediate cell survival via NF-κB (40) while removal or inhibition of the laminin-integrin-CD151-FAK axis markedly sensitizes HER2+ breast cancer cells to anti-HER2 agents including trastuzumab and lapatinib (41). Forthcoming studies should elucidate if the biochemical mechanisms by which constitutively active IGF-1R allows a highly-migratogenic phenotype in basal/HER2+ breast cancer cells can relate also to trastuzumab refractoriness via downstream activation of pro-survival/anti-apoptotic signaling such as NF-κB.

In summary, our current definition of novel secretomic and phospho-proteomic signatures in a basal/HER2+ breast carcinoma model may provide new insights into the ultimate molecular mechanisms underlying de novo refractoriness to HER-targeted therapies including trastuzumab. Although both the secretomic and phospho-proteomic features of JIMT-1 cells might eventually provide new targets for circumventing de novo resistance to trastuzumab in HER2+ breast carcinomas, their ultimate biological function regarding trastuzumab efficacy should be validated by employing pharmacological and/or siRNA-based approaches. Immuno-histochemical and/or microarray-based studies in breast cancer tissues should validate the notion that identification of progenitor (basal-like) phenotypes within HER2+ breast carcinomas may provide a rapid means to define subgroups of HER2-over-expressing breast cancer patients likely to display resistance to HER targeting therapies ab initio.

Acknowledgments

Alejandro Vazquez-Martín is the recipient of a Sara Borrell post-doctoral contract (CD08/00283, Ministerio de Sanidad y Consumo, Fondo de Investigación Sanitaria (FIS), Spain). Work at the Menendez Laboratory is supported by the Instituto de Salud Carlos III (Ministerio de Sanidad y Consumo, Fondo de Investigación Sanitaria (FIS), Spain, Grants CP05-0090 and PI06-0778 and RD06-0020-0028), the Fundación Científica de la Asociación Española Contra el Cáncer (AECC, Spain), and by the Ministerio de Ciencia e Innovación (SAF2009-11579, Plan Nacional de I+D+I, MCIINN, Spain). This work was also supported by a charity collection organized by the Fundación Roses Contra el Cáncer (Roses, Girona, Catalonia).

References


